YM-348

YM-348
Systematic (IUPAC) name
(2S)-1-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)propan-2-amine
Identifiers
CAS Number 372163-84-3
PubChem CID 3045225
IUPHAR/BPS 230
ChemSpider 2308001
Chemical data
Formula C14H17N3O
Molar mass 243.31 g·mol−1
  (verify)

YM-348 is an indazole derivative drug which acts as a potent and selective 5-HT2C receptor agonist, with an EC50 of 1nM and 15x selectivity over 5-HT2A, although it only has moderate selectivity of 3x over the closely related 5-HT2B receptor.[1][2] It has thermogenic and anorectic effects in animal studies, making it potentially useful for the treatment of obesity.[3][4][5][6]

See also

References

  1. Kimura, Y; Hatanaka, K; Naitou, Y; Maeno, K; Shimada, I; Koakutsu, A; Wanibuchi, F; Yamaguchi, T (2004). "Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist". European Journal of Pharmacology 483 (1): 37–43. doi:10.1016/j.ejphar.2003.10.004. PMID 14709324.
  2. Shimada, I; Maeno, K; Kazuta, K; Kubota, H; Kimizuka, T; Kimura, Y; Hatanaka, K; Naitou, Y; et al. (2008). "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry 16 (4): 1966–82. doi:10.1016/j.bmc.2007.10.100. PMID 18035544.
  3. Hayashi, A; Sonoda, R; Kimura, Y; Takasu, T; Suzuki, M; Sasamata, M; Miyata, K (2004). "Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats". Brain Research 1011 (2): 221–7. doi:10.1016/j.brainres.2004.03.032. PMID 15157808.
  4. Smith, BM; Thomsen, WJ; Grottick, AJ (2006). "The potential use of selective 5-HT2C agonists in treating obesity". Expert Opinion on Investigational Drugs 15 (3): 257–66. doi:10.1517/13543784.15.3.257. PMID 16503763.
  5. Nilsson, BM (2006). "5-Hydroxytryptamine 2C (5-HT2C) receptor agonists as potential antiobesity agents". Journal of Medicinal Chemistry 49 (14): 4023–34. doi:10.1021/jm058240i. PMID 16821762.
  6. Wacker, DA; Miller, KJ (2008). "Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases". Current opinion in drug discovery & development 11 (4): 438–45. PMID 18600561.


This article is issued from Wikipedia - version of the Sunday, April 03, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.